DUARTE, Calif.--(BUSINESS WIRE)--City of Hope announced today that it will present new research on bispecific antibodies at a press briefing during the ASH 63rd Annual Meeting and Exposition on Dec. 11 to 14 in Atlanta.

Other innovative City of Hope research on stem cell transplants and blood cancer treatments will also be presented during the conference organized by ASH. ASH is the world's largest professional society for clinicians and scientists around the world who are working on blood cancers and other hematological diseases.

City of Hope is finding new treatments for some of the hardest to treat cancers by accelerating innovative clinical research and therapies. The comprehensive cancer centers bone marrow transplant program is one of the largest and most successful in the nation and its chimeric antigen receptor (CAR) T cell therapy program is also focused on finding new therapies. City of Hope is leading other innovative immunotherapy treatments for blood cancers.

Elizabeth Budde, M.D, Ph.D., associate professor, City of Hope Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, will present research on a bispecific antibody mosunetuzumab for relapsed/refractory follicular lymphoma at an ASH press briefing titled Immune System 1, Cancer 0: Advances in Immunotherapy on Saturday, Dec. 11 at 8:30 a.m. ET Follicular lymphoma is associated with frequent relapses and decreasing progression-free intervals with successive lines of conventional therapy. Later-line treatments may be less effective due to refractory disease. Mosunetuzumab is a CD20xCD3 bispecific antibody that redirects T cells to eliminate malignant B cells. In the dose-escalation phase of an ongoing Phase I/II study (NCT02500407), Mosunetuzumab was highly active and well tolerated in R/R FL patients (pts).

Dr. Budde will also present the research at a plenary session.

Title: Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received 2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study Publication Number: 127Type: OralSession Name: 623. Mantle Cell, Follicular and Other B Cell Lymphomas: Clinical and Epidemiological: Evolution of Immunotherapeutic Regimens in B Cell LymphomasSession Date and Time: Saturday, Dec. 11, 2021, Noon to 1:30 p.m. ETPresentation Time: Saturday, Dec. 11, 2021, Noon ET

During the ASH conference, additional City of Hope researchers will also make presentations onsite or virtually:

Title: Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade Publication Number: 234Type: Oral.Session Name: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Hodgkin Lymphoma Clinical TrialsSession Date and Time: Saturday, Dec. 11, 2021, 2 to 3:30 p.m. ET Presentation Time: Saturday, Dec. 11, 2021, 3:15 p.m. ETPresenter: Alex Herrera, M.D., associate professor, City of Hope Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation

Herrera will also introduce an abstract at a plenary scientific session on Sunday, Dec. 12, 2 to 4 p.m. ET

Title: A Randomized Open Label Pilot Study of Clostridium Butyricum Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation Publication Number: 334Type: OralSession Name: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Infection and Immune ReconstitutionSession Date and Time: Saturday, Dec. 11, 2021, 4 to 5:30 p.m. ET Presentation Time: Saturday, Dec. 11, 2021, 4:45 p.m. ETPresenter: Karamjeet S. Sandhu, M.D., assistant professor, City of Hope Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation

Title: The Impact of Somatic Mutations on Allogeneic Hematopoietic Cell Transplantation in Chronic Myelomonocytic Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis Publication Number: 417Type: OralSession Name: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Prognostic Biomarkers for Donor Selection and Recipient OutcomesSession Date and Time: Sunday, Dec. 12, 2021, 9:30 a.m. to 11 a.m. ET Presentation Time: Sunday, Dec. 12, 2021, 10 a.m. ETPresenter: Matthew G. Mei, M.D., associate professor, City of Hope Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation

In addition, Andrew Artz, M.D., M.S., professor, City of Hope Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, will speak at an education session titled How Can We Ensure That Everyone Who Needs a Transplant Can Get One? about allogeneic hematopoietic cell transplantation for older adults and will also give opening remarks a scientific workshop on hematology and aging.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hopes translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nations Best Hospitals in cancer by U.S. News & World Report. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona. Translational Genomics Research Institute (TGen) became a part of City of Hope in 2016. AccessHope, a subsidiary launched in 2019, serves employers and their health care partners by providing access to NCI-designated cancer center expertise. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

Continue reading here:
City of Hope Doctors Present New Research on Cancer Immunotherapies - Business Wire

Comments are closed.